A exclusive authorisation agreement for Zemcelpro® in Europe signed by Avanzanite
A marketing authorisation in the European Union has been obtained by Zemcellpro of Avanzanite for adult patients with haematological adverse reactions which meet the criteria for administration, require different transgenic transformations of hemolytic malastocycitis and no other...
IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.
2 reports · 2 sources
NaftemporikiA exclusive authorisation agreement for Zemcelpro® in Europe signed by AvanzaniteNaftemporikiA exclusive authorisation agreement for Zemcelpro® in Europe signed by Avanzanite9 recorded states
Signal first indexedP1 · 68% quality · 1 source
Corroboration 1→2 sources · quality 68→72P1 · 72% quality · 2 sources
Quality 72→76P1 · 76% quality · 2 sources
Quality 76→80P1 · 80% quality · 2 sources
Quality 80→84P1 · 84% quality · 2 sources
Quality 84→88P1 · 88% quality · 2 sources
Quality 88→92P1 · 92% quality · 2 sources
Quality 92→96P1 · 96% quality · 2 sources
Quality 96→99P1 · 99% quality · 2 sources